Result of AGM

RNS Number : 0884W

Evocutis PLC

24 January 2012

 



Press Release

24 January 2012

Evocutis plc

("the Company")

Result of AGM

Evocutis plc (AIM:EVO), the company focussed on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, announces that all resolutions proposed at the Company's Annual General Meeting held today were duly passed.

- Ends -

For further information please contact Evocutis plc:

Evocutis plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman	www.evocutis.com

Nominated Adviser - Zeus Capital Ltd
Tom Rowley / Andrew Jones	Tel: [phone]
	www.zeuscapital.co.uk

Broker - XCAP Securities plc
Karen Kelly	Tel: [phone]
John Grant	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Adam Michael / Jamie Hooper	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

About Evocutis plc

With a rich portfolio of new product opportunities, Evocutis offers antimicrobial and dermatological expertise to the cosmetic, consumer healthcare and pharmaceutical industries.  Being uniquely able to combine research for laboratory testing, advanced skin models and clinical testing, Evocutis offers a complete service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products that actually work.

Offering high quality contract research services, Evocutis specialises in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research. Unique characteristics of its colonised full thickness model of human skin (LabSkin™) allow rapid, cost effective screening of, for example, anti-ageing, anti-inflammatory and antimicrobial ingredients and products for use on skin. Additionally, the clinical, human volunteer testing facility that is housed on-site  provides rapid, bespoke evaluation of dermatological products.

When it comes to advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, the Evocutis focus is simple: intelligent and specialised R&D input. 

For further information, please see www.evocutis.com

 

END

 

 

RAGXZLFLLFFXBBZ